Faisal Khurshid
Stock Analyst at Leerink Partners
(4.22)
# 397
Out of 5,090 analysts
28
Total ratings
50%
Success rate
21.61%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Maintains: Outperform | $13 → $16 | $13.47 | +18.78% | 2 | Nov 20, 2025 | |
| ABCL AbCellera Biologics | Downgrades: Market Perform | $4 | $3.56 | +12.36% | 2 | Nov 7, 2025 | |
| GLPG Galapagos NV | Upgrades: Outperform | $29 → $40 | $31.59 | +26.62% | 2 | Oct 21, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Outperform | $20 | $11.04 | +81.16% | 1 | Sep 25, 2025 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $73 | $89.65 | -18.57% | 1 | Sep 12, 2025 | |
| STTK Shattuck Labs | Maintains: Outperform | $4 → $2 | $3.10 | -35.48% | 2 | Aug 14, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $88 → $102 | $104.60 | -2.49% | 2 | Jul 10, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $3.48 | -71.26% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $33.45 | +34.53% | 1 | Apr 8, 2025 | |
| NRIX Nurix Therapeutics | Initiates: Market Perform | $16 | $18.09 | -11.55% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $33 → $2 | $1.21 | +65.29% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $0.82 | +1,841.98% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 | $66.62 | -9.94% | 2 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $81.77 | -2.16% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $3.74 | +301.07% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $18.05 | +149.31% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.31 | +434.35% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $5.68 | +40.85% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.66 | +652.33% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $5.46 | +101.47% | 1 | Mar 21, 2023 |
Trevi Therapeutics
Nov 20, 2025
Maintains: Outperform
Price Target: $13 → $16
Current: $13.47
Upside: +18.78%
AbCellera Biologics
Nov 7, 2025
Downgrades: Market Perform
Price Target: $4
Current: $3.56
Upside: +12.36%
Galapagos NV
Oct 21, 2025
Upgrades: Outperform
Price Target: $29 → $40
Current: $31.59
Upside: +26.62%
Contineum Therapeutics
Sep 25, 2025
Initiates: Outperform
Price Target: $20
Current: $11.04
Upside: +81.16%
Protagonist Therapeutics
Sep 12, 2025
Initiates: Outperform
Price Target: $73
Current: $89.65
Upside: -18.57%
Shattuck Labs
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $3.10
Upside: -35.48%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $104.60
Upside: -2.49%
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $3.48
Upside: -71.26%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $33.45
Upside: +34.53%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $18.09
Upside: -11.55%
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.21
Upside: +65.29%
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $0.82
Upside: +1,841.98%
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $66.62
Upside: -9.94%
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $81.77
Upside: -2.16%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $3.74
Upside: +301.07%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $18.05
Upside: +149.31%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.31
Upside: +434.35%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $5.68
Upside: +40.85%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.66
Upside: +652.33%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $5.46
Upside: +101.47%